Susceptibility of heterozygous p53 deficient CBA mice to induction of liver proliferative lesions by phenobarbital after dimethylnitrosamine initiation

Journal of Toxicologic Pathology

Volumn 14, Issue 4, 2001, Pages 273-278

  Onodera, Hiroshi ^a   Mitsumori, Kunitoshi ^a,b   Takagi, Hisayoshi ^a   Yasuhara, Kazuo ^a   Koujitani, Takatoshi ^a   Tamura, Touru ^a   Imai, Toshio ^a   Hirose, Masao ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

Author keywords

Hepatocarcinogenesis; N nitrosodimethylamine; p53 knockout mice; Phenobarbital; Susceptibility

Indexed keywords

EID: 0038153529     PISSN: 09149198     EISSN: 09149198     Source Type: Journal    
DOI: 10.1293/tox.14.273     Document Type: Article

References (21)

1. Hollstein M, Sidransky D, Vogelstein B, and Harris CC. P53 mutations in human cancers. Science 1991; 253: 49-53.
2. Tennant RW, Spalding J, and French JE. Evaluation of transgenic mouse bioassays for identifying carcinogens and noncarcinogens. Mutation Res 1996; 365: 119-127.
3. Harvey M, McArthur MJ, Montgomery CA Jr., Butel JS, Bradley A, and Donehower LA. Spontaneous and carcinogen -induced tumorigenesis in p53- deficient mice. Nat Genet 1993; 5: 225-229.
4. Ozaki K, Sukata T, Yamamoto S, Uwagawa S, Seki T, Kawasaki H, Yoshitake A, Wanibuchi H, Koide A, Mori Y, and Fukushima S. High susceptibility of p53 (+/-) knockout mice to N-butyl-N-(4-hydroxybutyl)nitrosamine urinary bladder carcinogenesis and lack of frequent mutation in residual allele. Cancer Res 1998; 58: 3806-3811.
5. Yamamoto S, Min W, Lee CCR, Salim EI, Wanibuchi H, Sukata T, and Fukushima S. Enhacement of urinary bladder carcinogenesis in nullizygous p53-deficient mice by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Letters 1999; 135: 137-144.
6. Tsukada T, Tomooka Y, Takai S, Ueda Y, Nishikawa S, Yagi T, Tokunaga T, Takeda N, Suda Y, Abe S, Matsuo I, Ikawa Y, and Aizawa S. Enhanced proliferative potential in culture of cells from p53-deficient mice. Oncogene 1993; 8: 3312-3322.
7. Ohgaki H, Fukuda M, Tohma Y, Huang H, Stoica G, Tatematsu M, and LA Donehower. Effect of intragastric application of N-methylnitrosourea in p53 knockout mice. Mol Carcinogenesis 2000; 28: 97-101.
8. Takagi H, Mitsumori K, Nishikawa A, Onodera H, Furukawa F, Kasahara K, and Hirose M. Lack of carcinogenic sensitivity of the glandular stomach in heterozygous p53 knockout mice given N-methyl-N-nitrosourea in their drinking water for 26 weeks. Asian Pacific J Cancer Prevent 2000; 1: 1-10.
9. Johe ES, Sandra WC, Roderick TB, Julio CD, Dale LM, and Cari LA. Phenobarbital does not promote hepatic tumorigenesis in a twenty-six-week bioassay in p53 heterozygous mice. Toxicol Pathol 1998; 26: 492-500.
10. Sukata T, Morimura K, Tokuyama Y, Ozaki K, Uwagawa S, Wanibuchi H, Seki T, Yoshitake A, Tsuda H, and Fukushima S. Susceptibility to hepatocarcinogenesis of p53 knockout mice. Proceeding of 55th Annual Meeting of Jap. Cancer Association pp.265, 1996.
11. Kemp CJ. Hepatocarcinogenesis in p53-deficient mice. Mol Carcinogenesis 1995; 12: 132-136.
12. Balachandra Dass S, Thomas JB, Robert HH, and Daniel AC. Evaluation of the trasgenic p53+/- mouse for detecting genotoxic liver carcinogens in a short-term bioassay. Cancer Lett 1999; 143: 81-85.
13. Shi ST, Yang GY, Wang L, Xue Z, Feng B, Ding W, Xing EP, and Yang CS. Role of p53 gene mutations in human esophageal carcinogenesis: Results from immunohistochemical and mutation analyses of carcinomas and nearby non-cancerous lesions. Carcinogenesis 1999; 20: 591-597.
14. Mitsumori K, Onodera H, Shimo T, Yasuhara K, Takagi H, Koujitani T, Hirose M, Maruyama C, and Wakana S. Rapid induction of uterine tumors with p53 point mutations in heterozygous p53 deficient CBA mice given a single intraoeritoneal administration of N-ethyl-N-nitrosourea. Carcinogenesis 2000; 21: 1039-1042.
15. Smith GS, Walford RL, and Mickey RM. Lifespan and incidence of cancer and other diseases in selected long-lived inbred mice and their F1 hybrids. J Natl Cancer Inst 1973; 50: 1195-1213.
16. Armato U, Wu J, Menegazzi M, Menapace L, Ribecco M, Testolin L, Carcereri De Prati A, and Suzuki H. The in utero initiation with DMN alters the complement of cytosolic glutathione S-transferases and the phenobarbital-induced expression of c-jun and c-myc oncogenes in primary neonatal rat hepatocytes. Cytotechnology 1993; 11 (Suppl 1): S18-20.
17. Anderson LM, Logsdon D, Ruski S, Fox SD, Issaq HJ, Kovatch RM, and Riggs CM. Promotion by polychlorinated biphenyls of lung and liver tumors in mice. Carcinogenesis 1994; 15: 2245-2248.
18. Wolff GL, Morrissey RL, and Chen JJ. Susceptible and resistant subgroups in genetically identical populations: Response of mouse liver neoplasia and body weight to phenobarbital. Carcinogenesis 1986; 7: 1935-1937.
19. Sukata T, Ozaki K, Uwagawa S, Seki T, Wanibuchi H, Yamamoto S, Okuno Y, and Fukushima S. Organ-specific, carcinogen-induced increases in cell proliferation in p53deficient mice. Cancer Res 2000; 60: 74-79.
20. Takizawa T, Mitsumori K, Takagi H, Onodera H, Yasuhara K, Tamura T, and Hirose M. Modifying effects of flumequine on dimelhylnitrosamine-induced hepatocareinogenesis in heterozygous p53 dificient CBA mice. J Toxicol Pathol 2001; 14: 135-143.
21. Cheol Beom Park, Dae Joong Kim, Uehara N, Takasuka N, Baba-Toriyama H, and Tsuda H. Heterozygous p53-deficient mice are not susceptible to 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline(MeIQx) carcinogenicity. Cancer Lett 1999; 139: 177-182.